NASDAQ:ACRX - AcelRx Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.80 -0.10 (-3.45 %)
(As of 05/24/2019 01:35 AM ET)
Previous Close$2.90
Today's Range$2.76 - $2.89
52-Week Range$1.99 - $5.05
Volume879,792 shs
Average Volume2.04 million shs
Market Capitalization$220.96 million
P/E RatioN/A
Dividend YieldN/A
Beta2.16
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.

Receive ACRX News and Ratings via Email

Sign-up to receive the latest news and ratings for ACRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACRX
CUSIPN/A
Phone650-216-3500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.15 million
Book Value($0.10) per share

Profitability

Net Income$-47,150,000.00
Net Margins-2,374.87%

Miscellaneous

Employees61
Market Cap$220.96 million
Next Earnings Date8/1/2019 (Estimated)
OptionableOptionable

AcelRx Pharmaceuticals (NASDAQ:ACRX) Frequently Asked Questions

What is AcelRx Pharmaceuticals' stock symbol?

AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."

How were AcelRx Pharmaceuticals' earnings last quarter?

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) issued its earnings results on Wednesday, May, 8th. The specialty pharmaceutical company reported ($0.17) EPS for the quarter, beating the Zacks' consensus estimate of ($0.23) by $0.06. The specialty pharmaceutical company earned $0.27 million during the quarter, compared to analysts' expectations of $0.85 million. View AcelRx Pharmaceuticals' Earnings History.

When is AcelRx Pharmaceuticals' next earnings date?

AcelRx Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, August 1st 2019. View Earnings Estimates for AcelRx Pharmaceuticals.

What price target have analysts set for ACRX?

8 analysts have issued 1 year price targets for AcelRx Pharmaceuticals' stock. Their forecasts range from $6.50 to $10.00. On average, they expect AcelRx Pharmaceuticals' stock price to reach $8.0714 in the next twelve months. This suggests a possible upside of 188.3% from the stock's current price. View Analyst Price Targets for AcelRx Pharmaceuticals.

What is the consensus analysts' recommendation for AcelRx Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AcelRx Pharmaceuticals.

What are Wall Street analysts saying about AcelRx Pharmaceuticals stock?

Here are some recent quotes from research analysts about AcelRx Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician's office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. " (5/23/2019)
  • 2. LADENBURG THALM/SH SH analysts commented, "We are not at all dismayed by the relatively small revenues since there is no stocking for this direct shipment product and hospital formularies barely had an opportunity to meet during these five weeks. Management did note that among the five hospital formularies that did meet, all five have approved Dsuvia. Presently, the company knows of 41 more meetings by midyear. If approved, it will still take weeks to months for AcelRx’s Dsuvia reps to find time with these busy hospital/ASC healthcare practitioners (HCPs), REMS training to be completed (relatively brief however) and the product to be stocked. As many investors know, hospital launches are notoriously slow. However, the early signals are ahead of our expectations." (5/9/2019)

Has AcelRx Pharmaceuticals been receiving favorable news coverage?

Headlines about ACRX stock have been trending somewhat positive on Friday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AcelRx Pharmaceuticals earned a media sentiment score of 1.9 on InfoTrie's scale. They also assigned media stories about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days.

Who are some of AcelRx Pharmaceuticals' key competitors?

What other stocks do shareholders of AcelRx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Ultra Clean (UCTT), Mattel (MAT), General Electric (Ge), Twitter (TWTR), Advanced Micro Devices (AMD), Novavax (NVAX), American National BankShares (AMNB), Enterprise Bancorp (EBTC), General Motors (GM) and US Foods (USFD).

Who are AcelRx Pharmaceuticals' key executives?

AcelRx Pharmaceuticals' management team includes the folowing people:
  • Mr. Vincent J. Angotti, CEO & Director (Age 51)
  • Dr. Pamela Pierce Palmer, Co-Founder, Chief Medical Officer & Director (Age 56)
  • Mr. Raffi Mark Asadorian, Chief Financial Officer (Age 50)
  • Mr. Lawrence G. Hamel, Chief Devel. Officer (Age 67)
  • Mr. Anil N. Dasu, Chief Engineering Officer (Age 56)

Who are AcelRx Pharmaceuticals' major shareholders?

AcelRx Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.07%), Laurion Capital Management LP (1.06%), Wells Fargo & Company MN (0.28%), ExodusPoint Capital Management LP (0.19%), Tibra Equities Europe Ltd (0.19%) and Citigroup Inc. (0.14%). Company insiders that own AcelRx Pharmaceuticals stock include Badri N Dasu, Lawrence G Hamel, Life Sciences Maste Perceptive, Mark G Edwards, Pamela P Palmer, Raffi Asadorian and Vincent J Angotti. View Institutional Ownership Trends for AcelRx Pharmaceuticals.

Which institutional investors are selling AcelRx Pharmaceuticals stock?

ACRX stock was sold by a variety of institutional investors in the last quarter, including Laurion Capital Management LP, Morgan Stanley, Jefferies Group LLC, Alpine Global Management LLC and Advisor Group Inc.. Company insiders that have sold AcelRx Pharmaceuticals company stock in the last year include Badri N Dasu and Lawrence G Hamel. View Insider Buying and Selling for AcelRx Pharmaceuticals.

Which institutional investors are buying AcelRx Pharmaceuticals stock?

ACRX stock was bought by a variety of institutional investors in the last quarter, including Tibra Equities Europe Ltd, Wells Fargo & Company MN, Citigroup Inc., BlackRock Inc., ExodusPoint Capital Management LP, Mercer Global Advisors Inc. ADV, Mercer Global Advisors Inc. ADV and Weiss Asset Management LP. Company insiders that have bought AcelRx Pharmaceuticals stock in the last two years include Mark G Edwards, Pamela P Palmer, Raffi Asadorian and Vincent J Angotti. View Insider Buying and Selling for AcelRx Pharmaceuticals.

How do I buy shares of AcelRx Pharmaceuticals?

Shares of ACRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AcelRx Pharmaceuticals' stock price today?

One share of ACRX stock can currently be purchased for approximately $2.80.

How big of a company is AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals has a market capitalization of $220.96 million and generates $2.15 million in revenue each year. The specialty pharmaceutical company earns $-47,150,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. AcelRx Pharmaceuticals employs 61 workers across the globe.

What is AcelRx Pharmaceuticals' official website?

The official website for AcelRx Pharmaceuticals is http://www.acelrx.com/.

How can I contact AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The specialty pharmaceutical company can be reached via phone at 650-216-3500 or via email at [email protected]


MarketBeat Community Rating for AcelRx Pharmaceuticals (NASDAQ ACRX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  394 (Vote Outperform)
Underperform Votes:  317 (Vote Underperform)
Total Votes:  711
MarketBeat's community ratings are surveys of what our community members think about AcelRx Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel